{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:46:07Z","timestamp":1768207567734,"version":"3.49.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The potential drug-drug interactions (pDDIs) seriously affecting the prognosis of colorectal cancer (CRC) patients. This study aimed to identify the risk factors of pDDIs in hospitalized CRC patients and construct a risk prediction model to provide a reference for clinical rational drug use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted, enrolling 2,868 patients from a tertiary hospital. Medscape was used to assess pDDIs, and a risk prediction model was constructed based on independent risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,790 (62.41%) patients experienced at least one pDDIs, with 1,458 (50.84%) cases of severe pDDIs. The number of drug varieties, hypoalbuminemia, and treatment were independent risk factors. The area under the receiver operating characteristic curve (AUC) of the model in the training and validation sets were 0.826 and 0.824, respectively. The calibration curve showed a good agreement between the predicted probability and the actual occurrence probability. Decision curve analysis (DCA) demonstrated that the model had a positive net clinical benefit within a wide range of 10%\u201390%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The constructed model has good predictive performance and can be used to identify high-risk patients with pDDIs in clinical practice, thereby improving the safety of drug use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1714838","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:43:52Z","timestamp":1768196632000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk prediction model for severe potential drug-drug interactions in colorectal cancer patients: a real-world data study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaomei","family":"Pei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingti","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12877-025-05965-y","article-title":"Potential drug-drug interactions among geriatric oncology patients: a retrospective study in Saudi Arabia","volume":"25","author":"Alkathiri","year":"2025","journal-title":"BMC Geriatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"20420986231154365","DOI":"10.1177\/20420986231154365","article-title":"Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using national reporting and learning system (NRLS) data from England and Wales: a multi-method study","volume":"14","author":"Alqenae","year":"2023","journal-title":"Ther. Adv. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/FTD.0000000000000403","article-title":"A retrospective study on mycophenolic acid drug interactions: effect of prednisone, sirolimus, and tacrolimus with MPA","volume":"39","author":"Alvarez-Elias","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"B4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/10781552221074629","article-title":"Evaluation of potential drug-drug interactions in cancer patients at a tertiary care hospital in Pakistan","volume":"28","author":"Choudary","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/14740338.2024.2346101","article-title":"Incidence and risk factors for potential drug-drug interactions in outpatients receiving opioid analgesics","volume":"24","author":"Chu","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000538742","article-title":"Potential drug-drug interactions in outpatient lung cancer patients in a university hospital","volume":"109","author":"Demirkapu","year":"2024","journal-title":"Pharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1525079","DOI":"10.3389\/fpubh.2025.1525079","article-title":"Polypharmacy, drug-drug interactions, and potentially inappropriate medications among older adults: a cross-sectional study in northeast Ethiopia","volume":"13","author":"Endalifer","year":"2025","journal-title":"Front. Public Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.2147\/IDR.S536758","article-title":"Real-world analysis of potential drug-drug interactions with nirmatrelvir\/Ritonavir based on the hospital prescription analysis (HPA) database in 9 cities of China","volume":"18","author":"Guo","year":"2025","journal-title":"Infect. Drug Resist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1586300","DOI":"10.3389\/fphar.2025.1586300","article-title":"Prediction of early mucosal healing of Crohn's disease after treatment with biologics-a novel nomogram based on radiomics and clinical risk factors","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1546465","DOI":"10.3389\/fphar.2025.1546465","article-title":"Effect of hypoalbuminemia on drug pharmacokinetics","volume":"16","author":"Idasiak-Piechocka","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12885-020-06855-9","article-title":"Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy","volume":"20","author":"Ismail","year":"2020","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/87551225241241977","article-title":"Clinical pertinence and determinants of potential drug-drug interactions in chronic kidney disease patients: a cross-sectional study","volume":"40","author":"Khanna","year":"2024","journal-title":"J. Pharm. Technol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00129785-200505010-00002","article-title":"Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications","volume":"5","author":"Lentz","year":"2005","journal-title":"Am. Journal Pharmacogenomics Genomics-Related Research Drug Development Clinical Practice"},{"key":"B16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/TCRM.S399218","article-title":"Evaluating efficacy and safety of tacrolimus treatment in membranous nephropathy: results of a retrospective study of 182 patients","volume":"19","author":"Liang","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.62347\/WFPE2805","article-title":"Comparative effects of oxaliplatin-based versus irinotecan-based regimens combined with capecitabine and bevacizumab in patients with colorectal cancer and liver metastases","volume":"15","author":"Liang","year":"2025","journal-title":"Am. Journal Cancer Research"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1071816","DOI":"10.3389\/fonc.2023.1071816","article-title":"Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma","volume":"13","author":"Lin","year":"2023","journal-title":"Front. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1455721","DOI":"10.3389\/fphar.2024.1455721","article-title":"Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis","volume":"15","author":"Ling","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/17425255.2025.2551724","article-title":"Language models for drug-drug interactions: current applications, pitfalls, and future directions","volume":"21","author":"Meslamani","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000540427","article-title":"Drug-drug interactions in hospitalized urological patients: a retrospective cohort study","volume":"110","author":"Milovanovic","year":"2025","journal-title":"Pharmacology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s40262-025-01558-5","article-title":"Malnutrition and its effect on drug pharmacokinetics: a clinical perspective","volume":"64","author":"Ngcobo","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/curroncol32080455","article-title":"Understanding chemotherapy-induced thrombocytopenia: implications for gastrointestinal cancer treatment","volume":"32","author":"Peshin","year":"2025","journal-title":"Curr. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/1574886317666220324100356","article-title":"Potential drug-drug interactions between anti-cancer drugs and other medications in lung cancer patients: a retrospective study","volume":"18","author":"Pinto","year":"2023","journal-title":"Curr. Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e82770","DOI":"10.7759\/cureus.82770","article-title":"Therapeutic drug-drug interactions (DDIs) causing QT prolongation in patients with cancer: a systematic review and meta-analysis","volume":"17","author":"Ramasubbu","year":"2025","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1558830","DOI":"10.3389\/fphar.2025.1558830","article-title":"From prescription patterns to drug safety: a closer look at non-steroidal anti-inflammatory drugs and analgesics in outpatient pharmacy","volume":"16","author":"Saeed","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e37078","DOI":"10.1097\/MD.0000000000037078","article-title":"Effect of hypoproteinemia on mortality of elderly male patients with chronic heart failure","volume":"103","author":"Tan","year":"2024","journal-title":"Med. Baltim."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1563506","DOI":"10.3389\/fphar.2025.1563506","article-title":"Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients","volume":"16","author":"Tang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3238\/arztebl.m2024.0172","article-title":"Clinical practice guideline: recommendations for the perioperative management of pancreatic and colorectal cancer patients","volume":"121","author":"Vilz","year":"2024","journal-title":"Dtsch. Arztebl Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.2147\/IDR.S406852","article-title":"Ertapenem-induced neurotoxicity: a literature review of clinical characteristics and treatment outcomes","volume":"16","author":"Wang","year":"2023","journal-title":"Infect. Drug Resist"},{"key":"B31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/cac2.12639","article-title":"The Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update","volume":"45","author":"Wang","year":"","journal-title":"Cancer Commun. (Lond)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e19676","DOI":"10.7717\/peerj.19676","article-title":"Development and validation of a risk prediction model for hypoproteinemia after adult cardiac valve surgery: implications for clinical care","volume":"13","author":"Wang","year":"","journal-title":"PeerJ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e077863","DOI":"10.1136\/bmjopen-2023-077863","article-title":"Potential drug-drug interaction and its determinants among patients with cancer receiving chemotherapy in oncology centres of northwest Ethiopia: an institutional-based cross-sectional study","volume":"13","author":"Wondm","year":"2023","journal-title":"BMJ Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.dld.2025.06.007","article-title":"Machine learning models for predicting chemotherapy-induced adverse drug reactions in colorectal cancer patients","volume":"57","author":"Wu","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/1120009X.2024.2376453","article-title":"Development and validation of a clinical risk score nomogram for predicting voriconazole trough concentration above 5 mg\/L: a retrospective cohort study","volume":"37","author":"Xie","year":"2025","journal-title":"J. Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1569689","DOI":"10.3389\/fimmu.2025.1569689","article-title":"Development of a lung immune prognostic index-based nomogram model for predicting overall survival and immune-related adverse events in non-small cell lung cancer patients treated with sintilimab","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.2147\/DDDT.S514173","article-title":"A population pharmacokinetics study of venetoclax concomitant with voriconazole in patients with hematologic malignancies","volume":"19","author":"Yang","year":"2025","journal-title":"Drug Des. Devel Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1519766","DOI":"10.3389\/fimmu.2025.1519766","article-title":"A nomogram integrating the clinical and CT imaging characteristics for assessing spread through air spaces in clinical stage IA lung adenocarcinoma","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"101558","DOI":"10.1016\/j.esmoop.2023.101558","article-title":"Pan-asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer","volume":"8","author":"Yoshino","year":"2023","journal-title":"ESMO Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.3390\/pharmaceutics15092274","article-title":"Translational pharmacokinetic\/pharmacodynamic modeling and simulation of oxaliplatin and irinotecan in colorectal cancer","volume":"15","author":"Zhu","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714838\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:43:53Z","timestamp":1768196633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714838\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":40,"alternative-id":["10.3389\/fphar.2025.1714838"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1714838","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1714838"}}